A Phase 1 and Pharmacologic Study of MM-111 in Combination With Multiple Treatment Regimens in Patients With Advanced HER2 Positive Solid Tumors

Trial Profile

A Phase 1 and Pharmacologic Study of MM-111 in Combination With Multiple Treatment Regimens in Patients With Advanced HER2 Positive Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Dec 2015

At a glance

  • Drugs MM 111 (Primary) ; Capecitabine; Cisplatin; Docetaxel; Lapatinib; Paclitaxel; Trastuzumab
  • Indications Advanced breast cancer; Colorectal cancer; Gastric cancer; Oesophageal cancer; Ovarian cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Merrimack Pharmaceuticals
  • Most Recent Events

    • 30 Sep 2014 According to a Merrimack Pharmaceuticals media release, biomarker data was presented at the European Society of Medical Oncology (ESMO) 2014 Congress.
    • 01 Aug 2014 Status changed from active, no longer recruiting to completed, according to results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
    • 03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top